• News
  • Cases
  • Downloads
14.09.2019
Jesse Hsu, Taplow China Business Partner shares his experience in Beijing on 19th July 2019 and in Shanghai on July 23rd, 2019. The discussion was...
Taplow’s Senior Business Partner Shares Experiences in Beijing on 19 July 2019 and in Shanghai on July 23 rd.
14.09.2019
Taplow roundtable conference took place in Beijing on 26th April 2019, where 19 executives from various industries and fields participated. The...
Roundtable Conference in Beijing on 26 April 2019.
13.07.2019
Commenting on Taplow featuring once again in one of the industries leading publications survey, Mark Firth, Managing Partner - UK and...
Taplow listed in global survey for 5th consecutive year.
12345

CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here